Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch
about
Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settingsFeasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South AfricaAssociation of first-line and second-line antiretroviral therapy adherence.Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaHIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settingsCan Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa.Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study.Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.Pill aversion in HIV-infected pregnant women: Theory to practice.Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.When patients fail UNAIDS' last 90 - the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a prospective cohort study.Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes.Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysiSESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-la
P2860
Q28543578-9424CFC1-EE8E-4702-97C5-AE85766EF8D9Q30238931-376C18DA-5433-45E1-80FD-9C42482FBEDEQ33712438-C0092295-FECF-4F54-9A2D-0EC0982B047AQ33733440-C784A962-259D-4A53-AA6B-1933403CB4AAQ33777513-A9019ECB-53CC-4350-A6AE-0C3C428238FDQ34801978-9789E9FF-4E05-471A-86B7-93832D1008B0Q35853812-7CDFDE3E-08B0-4942-AED3-072E3E6F7BE8Q36015636-A28C9F11-0BF2-44D8-89CD-5C2FF5E55248Q36769221-E51BB9C8-B6DB-485E-87C3-B3709181B1D2Q37116750-CF609613-9178-47ED-9825-1F2EE30D8836Q37348464-93E5C345-EC7D-401C-9463-F4C00E51F5AAQ37516995-917F0AD0-E0F3-469C-AB0B-848C8DBBAD57Q37634044-13F7CD17-EED3-4F2F-A45F-C459E1CCC4AFQ37677959-413458E2-C846-4613-89B7-81C04EB825E8Q38853866-DB482D62-20A0-4AB0-891D-300368772621Q38954109-1C0EC617-6E11-4093-B45C-B49B2178F787Q39155386-F4395F9B-0F72-483A-B76B-88CE099F0B79Q46854529-9EDA07CC-67C0-43B8-89C0-552476CCACF5Q47258937-9E4E1F96-5175-477D-89A5-D7921C0FE9BFQ49344179-47F97696-5E68-457B-BABB-66BB08813FCE
P2860
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Viral suppression following sw ...... concentrations prior to switch
@en
Viral suppression following sw ...... oncentrations prior to switch.
@nl
type
label
Viral suppression following sw ...... concentrations prior to switch
@en
Viral suppression following sw ...... oncentrations prior to switch.
@nl
prefLabel
Viral suppression following sw ...... concentrations prior to switch
@en
Viral suppression following sw ...... oncentrations prior to switch.
@nl
P2093
P2860
P50
P356
P1476
Viral suppression following sw ...... concentrations prior to switch
@en
P2093
Alison D Grant
Andrew Phillips
Gavin Churchyard
Johanna Ledwaba
Victoria Johnston
P2860
P304
P356
10.1093/INFDIS/JIT411
P407
P577
2013-08-13T00:00:00Z